Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCO-101 plus FOLFIRI in FOLFIRI-Resistant mCRC
NCT04247256Phase 2Unknown
- Sponsor
- Scandion Oncology
- Start
- May 2020
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of sco-101 in metastatic colorectal cancer (mCRC), sponsored by Scandion Oncology. Status: unknown.
02
Drugs
sco-101
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT04247256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04247256.